BRIEF-Aeglea Biotherapeutics receives FDA fast track designation for AEB1102
May 23, 2016 at 16:10 PM EDT
* Aeglea Biotherapeutics receives FDA fast track designation for AEB1102 for treatment of patients with hyperargininemia secondary to Arginase I deficiency
